Supplementary Data (Supplementary Figure legends and Figures)
Kitadate et al.
Multiple myeloma with t(11;14)-associated immature plasma cell phenotype has lower CD38 expression and higher BCL2 dependence

Supplementary Figure legends

Figure S1. Ex vivo CDC and ADCC assays in myeloma patients with or without lymphoplasmacytoid morphology. Bone marrow mononuclear cells from 48 patients with newly diagnosed MM were used in ADCC and CDC assays with 10 μg/ml daratumumab. ADCC and CDC assays were performed as described in Materials and Methods. Bars indicate the median with interquartile range. Significance was assessed by Kruskal-Wallis test.

Figure S2. CDC assay of KMS12BM and NCU-MM1 cell lines treated with ATRA. Cells were treated with 1 μM ATRA, or the DMSO control, for 72 h before daratumumab treatment. Lysis of myeloma cells via CDC was measured by flow cytometry after measuring the percentage of propidium iodide-positive cells. Myeloma cell lysis was determined after counting viable cells within the CD138-positive cell population. ATRA-pretreated KMS12BM and NCU-MM1 cells were treated with daratumumab (10 μg/mL) and pooled human serum as source of complement for 1 h prior to flow cytometric analysis. Complement-dependent lysis was calculated using the following formula: % lysis = 1 − (absolute number of surviving CD138+ cells in the presence of native human serum/absolute number of surviving CD138+ cells in the presence of heat-inactivated serum) × 100%. Bars indicate the mean ± standard error of three independent experiments. Significance of differences between the indicated groups was assessed by Student’s t-tests.
Figure S2

% lysis of myeloma cells

KMS12BM | NCU-MM1
---|---
DMSO | ATRA

[***] [***]